RecruitingNCT07215975
A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East
REal-World Application of Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East (RELATE): A Non-interventional Retrospective and Prospective Observational Study
Sponsor
Bristol-Myers Squibb
Enrollment
200 participants
Start Date
Jun 25, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to evaluate luspatercept treatment in adults with transfusion-dependent beta-Thalassemia in the Middle East
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Male or female participants of any race aged at least 18 years at time of initiation of luspatercept treatment
- Participants with documented diagnosis of transfusion-dependent β-thalassemia (TDT).
- Participants who have been initiated on treatment with luspatercept as per the product's Summary of Product Characteristics (SmPC) no longer than 12 months prior to informed consent signature, and for whom therapy is ongoing.
- Participants for whom the decision to prescribe luspatercept treatment is clearly separated from the physician's decision to include the participant in the current study.
- Participants who have provided signed informed consent for participating in the study and for collecting and analyzing medical data pertinent to the objectives of this study
Exclusion Criteria4
- Participants that meet any of the contraindications to the administration of luspatercept as outlined in the latest version of the locally approved SmPC.
- Participants who are currently receiving or are planned to receive treatment with any investigational drug/device/intervention or who have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) prior to luspatercept therapy initiation.
- Participants who are currently pregnant, breastfeeding, or planning a pregnancy during the study observation period.
- Participants who have not provided signed informed consent for participating in the study and for collecting and analysing medical data pertinent to the objectives of this study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGLuspatercept
According to the product label
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07215975
Related Trials
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226105 locations
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
NCT057364196 locations
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
NCT054775636 locations
A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia
NCT063024915 locations
Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
NCT063133981 location